1. Raghu G., Collard H.R., Egan J.J. et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis; evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183 (6): 788-824. https://doi.org/10.1164/rccm.2009-040GL.
2. Raghu G., Rochwerg B., Zhang Yu. et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2015; 192: (2) 3-19. https://doi.org/10.1164/rccm.201506-1063ST.
3. Travis W.D., Costabel U., Hansell D.M. et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013; 188 (6): 733-748. https://doi.org/10.1164/rccm.201308-1483ST.
4. Ryu J.H., Moua T., Daniels C.E. et al. Idiopathic pulmonary fibrosis: evolving concepts. Mayo Clin. Proc. 2014; 89: (8) 1130-1142. https://doi.org/10.1016/j.mayocp.2014.03.016.
5. Raghu G., Weycker D., Edelsberg J. et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2006; 174 (7): 810-816. https://doi.org/10.1164/rccm.200602-163OC.
6. Richeldi L., Rubin A.S., Avdeev S. et al. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Medicine. 2015; 13: 237. https://doi.org/10.1186/s12916-015-0495-0.
7. Meltzer E.B., Noble P.W. Idiopathic pulmonary fibrosis. Orphanet. J. Rare Dis. 2008; 3: 8. https://doi.org/10.1186/1750-1172-3-8.
8. Chuchalin A.G., Avdeev S.N., Aisanov Z.R. et al. Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis. Federal Guidelines. Pul'monologiya. 2016; 26 (4): 399-419. https://doi.org/10.18093/0869-0189-2016-26-4-399-419 (in Russian).
9. Davies H.R., Richeldi L., Walters E.H. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. 2003; 3: CD003134. https://doi.org/10.1002/14651858.CD003134.
10. von Suesskind-Schwendi M., Boxhammer E., Hirt S.W. et al. The activity of nintedanib in an animal model of allogenic left lung transplantation resembling aspects of allograft rejection. Exp. Lung Res. 2017; 43 (6-7): 259-270. https://doi.org/10.1080/01902148.2017.1354408.
11. Flaherty K.R., Toews G.B., Lynch J.P. 3rd et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am. J. Med. 2001; 110 (4): 278-282. https://doi.org/10.1016/S0002-9343(00)00711-7.
12. Raghu G., Anstrom K.J., King T.E. Jr et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 2012; 366 (21): 1968-1977. https://doi.org/10.1056/NEJMoa1113354.
13. Martinez F.J., de Andrade J.A., Anstrom K.J. et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370 (22): 2093-2101. https://doi.org/10.1056/NEJMoa1401739.
14. King T.E. Jr, Bradford W.Z., Castro-Bernardini S. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370 (22): 2083-2092. https://doi.org/10.1056/NEJMoa1402582.
15. Richeldi L., du Bois R.M., Raghu G. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370 (22): 2071-2082. https://doi.org/10.1056/NEJMoa1402584.
16. Wollin L., Maillet I., Quesniaux V. et al. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J. Pharmacol. Exp. Ther. 2014; 349 (2): 209-220. https://doi.org/10.1124/jpet.113.208223.
17. Hilberg F., Roth G.J., Krssak M. et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008; 68 (12):4774-4782. https://doi.org/10.1158/0008-5472.CAN-07-6307.
18. Sundarakrishnan A., Chen Y., Black L.D. et al. Engineered cell and tissue models of pulmonary fibrosis. Adv. Drug Deliv. Rev. 2017; Dec 18. pii: S0169-409X(17)30316-2. https://doi.org/10.1016/j.addr.2017.12.013. [Epub ahead of print].
19. Fukihara J., Kondoh Y. Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis. Exp. Rev. Respir. Med. 2016; 10 (12): 1247-1254. https://doi.org/10.1080/17476348.2016.1249854.
20. Schmid U., Doege C., Dallinger C., Freiwald M. Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis. Pulm. Pharmacol. Ther. 2018; 48: 136-143. https://doi.org/10.1016/j.pupt.2017.11.004.
21. Woodcock H.V., Molyneaux P.L., Maher T.M. Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib. Drug Des. Dev. Ther. 2013; 7: 503-510. https://doi.org/10.2147/DDDT.S38833.
22. Schaefer C.J., Ruhrmund D.W., Pan L. et al. Antifibrotic activities of pirfenidone in animal models. Eur. Respir. Rev. 2011; 20 (120): 85-97. https://doi.org/10.1183/09059180.00001111.
23. Macías-Barragán J., Sandoval-Rodríguez A., Navarro-Partida J., Armendáriz-Borunda J. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair. 2010; 3: 16. https://doi.org/10.1186/1755-1536-3-16.
24. Taniguchi H., Ebina M., Kondoh Y. et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J. 2010; 35 (4): 821-829. https://doi.org/10.1183/09031936.00005209.
25. Rubino C.M., Bhavnani S.M., Ambrose P.G. et al. Effect of food and antiacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm. Pharmacol. Ther. 2009; 22 (4): 279-285. https://doi.org/10.1016/j.pupt.2009.03.003.
26. Noble P.W., Albera C., Bradford W.Z. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377 (9779): 1760-1769. https://doi.org/10.1016/S0140-6736(11)60405-4.
27. Fleetwood K., McCool R., Glanville J. et al. Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments. J. Manag. Care Spec. Pharm. 2017; 23 (3-b, Suppl.): S5-S16. https://doi.org/10.18553/jmcp.2017.23.3-b.s5.
28. Canestaro W.J., Forrester S.H., Raghu G. et al. Drug treatment of idiopathic pulmonary fibrosis: a systematic review and network meta-analysis. Chest. 2016; 149 (3): 756-766. https://doi.org/10.1016/j.chest.2015.11.013.
29. Rogliani P., Calzetta L., Cavalli F. et al. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Pulm. Pharmacol. Ther. 2016; 40: 95-103. https://doi.org/10.1016/j.pupt.2016.07.009.
30. Crestani B., Kolb M., Wallaert B. et al. Long-Term Efficacy of Nintedanib Is Maintained in Patients with Idiopathic Pulmonary Fibrosis (IPF) Irrespective of Dose: Subgroup Analysis of INPULSIS-ON. Am. J. Respir. Crit. Care Med. 2017; 195: A5408.
31. Richeldi L., Kreuter M., Selman M. et al. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. Thorax. 2017. Oct 9. pii: thoraxjnl-2016-209701. https://doi.org/10.1136/thoraxjnl-2016-209701. [Epub ahead of print].
32. King T.E. Jr, Albera C., Bradford W.Z. et al. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am. J. Respir. Crit. Care Med. 2014; 189 (7): 825-831. https://doi.org/10.1164/rccm.201311-1951OC.
33. Loveman E., Copley V.R., Scott D.A. et al. Comparing new treatments for idiopathic pulmonary fibrosis - a network meta-analysis. BMC Pulm. Med. 2015; 15: 37. https://doi.org/10.1186/s12890-015-0034-y.
34. Rinciog C., Watkins M., Chang S. et al. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK. PharmacoEconomics. 2017; 35 (4): 479-491. https://doi.org/10.1007/s40273-016-0480-2.